Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

NCT01989780 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Paclitaxel
DRUG: Bevacizumab
DRUG: Letrozole
DRUG: Anastrozole
DRUG: Exemestane
DRUG: Fulvestrant
DRUG: Goserelin
DRUG: leuprorelin

Sponsor

Japan Breast Cancer Research Group

Collaborators

[object Object]